medigraphic.com
Boletín Médico del Hospital Infantil de México

2010, Number 6

<< Back Next >>

Bol Med Hosp Infant Mex 2010; 67 (6)

Pediatric cancer results in a population with limited resources in Bogota, Colombia

Buendía-Hernández A, Loboguerrero-Compagnoli J, Lozano-León JM

Language: Spanish
References: 47
Page: 518-535
PDF size: 414.33 Kb.


ABSTRACT

Background. Despite remarkable progress achieved for pediatric cancer, ›60% of children affected worldwide have little or no access to effective therapy. This study assessed the results of a pediatric cancer program in a limited resources setting.
Methods. A historical descriptive study with analytic component was conducted between 1990 and 2007 in 242 children ‹16 years of age at Clínica Infantil Colsubsidio in Bogotá, Colombia. Measures included international protocol-based therapy, day-hospital system for chemotherapy and blood-cell support provided by trained nurses, pediatric oncologist and hematologist staffed 8-h with 24-h on-site physician coverage, as well as rapid administrative support. Treatment failure rates and survival were compared during the study.
Results. An increase (40.5% to 63.3%) in survival (p =0.021) and a reduction in the referral for treatment (22.4% to 8.9%) to other centers (p =0.025) were observed during the study. There were also tendencies towards reduction in mortality due to acute complications (16.3-9.9%) and in frequency of those who refused or abandoned therapy (5.2 to 3%).The 10-year event-free-survival for acute lymphoblastic leukemia was 65%.
Conclusions. The strategy provided encouraging survival outcomes in a limited resources setting.


REFERENCES

  1. Bleyer WA. What can be learned about childhood cancer from “Cancer Statistics Review 1973-1988”. Cancer 1993;71:3229-3236.

  2. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997;90:4243-4251.

  3. Berg SL, Grisell DL, DeLaney TF, Balis FM. Principles of treatment of pediatric solid tumors. Pediatr Clin North Am 1991;38:249-267.

  4. Friedman HS, Horowitz M, Oakes WJ. Tumors of the central nervous system. Improvement in outcome through a multimodality approach. Pediatr Clin North Am 1991;38:381-391.

  5. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin lymphoma in childhood. N Engl J Med 1996;334:1238-1248.

  6. Petruzzi MJ, Green DM. Wilms’ tumor. Pediatr Clin North Am 1997;44:939-952.

  7. Gurney JG, Bondy ML. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 1-13.

  8. Howard SC, Pedrosa M, Lins M, Pedrosa A, Pui CH, Ribeiro RC, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004;291:2471-2475.

  9. Barr R, Ribeiro R, Agarwal B, Masera G, Hesseling P, Magrath I. Pediatric oncology in countries with limited resources. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 1604-1616.

  10. Ribeiro R, Pui CH. Saving the children—improving childhood cancer treatment in developing countries. N Engl J Med 2005;352:2158-2160.

  11. Nolan T, Angos P, Cunha AJ, Muhe L, Qazi S, Simoes EA, et al. Quality of hospital care for seriously ill children in less-developed countries. Lancet 2001;357:106-110.

  12. Masera G, Eden T, Schrappe M, Nachman J, Gadner H, Gaynon P, et al. Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;43:103-104.

  13. The World Bank. The Little Green Data Book 2006. Washington: Communications Development Incorporated; 2006.

  14. Rodgers CC. Resources for children with cancer, their families, and physicians. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 1629-1729.

  15. American Academy of Pediatrics Policy Statement. Organizational principles to guide and define the child health care system and/or improve the health of all children section on hematology/oncology. Guidelines for Pediatric Cancer Centers. Pediatrics 2004;113:1833-1835.

  16. Pasmantier MW, Coleman M, Silver RT, Mamaril AP, Quiguyan CC, Galindo A Jr. Administration of a complex chemotherapy regimen: inpatient versus outpatient treatment. Med Pediatr Oncol 1983;11:333-335.

  17. Jessop DJ, Stein RE. Who benefits from a pediatric home care program? Pediatrics 1991;88:497-505.

  18. Girmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L, et al. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of hematologic emergency unit. Haematologica 1999;84:814-819.

  19. Buendia MT, Lozano JM, Suarez G, Saavedra C, Guevara G. The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogotá-Colombia. J Pediatr Hematol Oncol 2008;30:643-650.

  20. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthacyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.

  21. Schrappe M, Castillo L, Masera G, Riehm H, Starý J, et al. ALL IC-BFM 2002. A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia. Trial Steering Committee Eds. Final version of Therapy Protocol (May 3, 2002).

  22. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990;75:1932-1940.

  23. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001;19:2705-2713.

  24. Magrath IT. Malignant non-Hodgkin’s lymphomas. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott; 1989. pp. 415-455.

  25. Buendia MT, Terselich G, Vega R, Suarez G, Castro E, Posso H. Outcome in extensive abdominal small non-cleaved cell lymphoma (SNCCL) in children. Results with COMP Therapy (abstract). Med Pediatr Oncol 1998;31:266.

  26. Magrath I. Malignant non-Hodgkin’s lymphomas in children. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott; 1993. pp. 537-575.

  27. Ritter J, Schellong G, Wannenmacher M. Treatment of Hodgkin´s disease in children. In: Riehm H, ed. Malignant Neoplasms in Childhood and Adolescence. New York: Karger; 1986. pp. 187-205.

  28. Buendia MT, Terselich G, Rueda E, Zea JM, Vega R, Barbosa G, et al. Retrospective analysis of 168 children with Hodgkin’s disease and long-term follow-up results (abstract). Med Pediatr Oncol 1994;23:228.

  29. Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billet AL, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol 2002;20:3081-3087.

  30. Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Children’s Cancer Study Group. J Neurooncol 1989;7:165-177.

  31. Duffner PK, Cohen ME. Treatment of brain tumors in babies and very young children. Pediatr Neurosci 1985-1986;12:304-310.

  32. Lashford LS, Campbell RH, Gattamaneni HR, Robinson K, Walker D, Bailey C. An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Child 1996;74:219-223.

  33. Packer R, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11:850-856.

  34. Kun LE. Brain tumors. Challenges and directions. Pediatr Clin North Am 1997;44:907-917.

  35. Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine and prednisone. J Neurosurg 1990;72:572-582.

  36. Gajjar A. Recent advances in therapy for medulloblastoma. In: American Society of Clinical Oncology, eds. 1999 Spring Educational Book. Alexandria: American Society of Clinical Oncology; 1999. pp. 579-586.

  37. Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464-469.

  38. D’Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, deLorimier A, et al. Treatment of Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer 1989;64:349-360.

  39. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PR, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 1998;16:237-245.

  40. Hayes FA, Smith EI. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincot; 1989. pp. 607-622.

  41. United Nations General Assembly. 11 October 2002. Twenty-seventh special session, “A world fit for children”, Resolution adopted by the general Assembly [on the report of the Ad Hoc committee of the whole (A/S-27/19/Rev.1 and corr. 1 and 2)] 6th plenary meeting 10 May 2002. A-RES-S27-2E [1].

  42. Berwick DM. Lessons from developing nations on improving health care. BMJ 2004;328:1124-1129.

  43. Blatt J, Copeland DR, Bleyer WA. Late effects of childhood cancer and its treatment. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott; 1993. pp. 1091-1114.

  44. American Academy of Pediatrics. Hepatitis B. In: Pickering LK, ed. Red Book (Libro Rojo). Memoria del Comité de Enfermedades Infecciosas para 2003. México: Intersistemas; 2004. pp. 383-403.

  45. Buitrago B. Patología geográfica: historia natural de las hepatitis B y D en Colombia. Biomédica 1991;11:5-26.

  46. Brown S, Belgaumi A, Ajarim D, Kofide A, Al Saad R, Sabbah R, et al. Loss to follow-up of patients with malignant lymphoma. Eur J Cancer Care (Engl) 2004;13:180-184.

  47. Conter V, Arico M, Valsecchi MG, Rizzari C, Testi AM, Messina C, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive-chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol 1995;13:2497-2502.




2020     |     www.medigraphic.com